Bristol-Myers Squibb receives CRL from FDA for daclatasvir
Bristol-Myers Squibb announced the FDA has issued a Complete Response Letter regarding the New Drug Application for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C. November 26, 2014